Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome

Trial Profile

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2016 Results (n=23) presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 03 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 16 Dec 2014 Data are expected in mid 2015, according to an Auspex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top